Anacor Pharmaceuticals Inc (NASDAQ:ANAC) was happy to announced that its phase III trials for the eczema treatment was a success.
The company’s shares went up due to the good news and thus pointing towards an FDA application. The trial period was a success in two clinical trials carried out on more than 1,500 patients. The treatment marked up significantly against the placebo, thus treating eczema within 29 days. According to the clinical data, the treatment was able to meet its primary endpoint or both trials thus significantly curing many if the patients with the condition.
There was a minimum improvement of about two grades for 32% of the eczema patients. On a different level, roughly half of the patients who had volunteered for the crisaborole treatment, most of them were either cleared or almost despite the time they joined on the scale.
Anacor claims that the side effects of the treatment were insignificant. Only 4.4% of the patients experienced at the point where the cream treatment was applied. 3% of the patients were found to have respiratory infections. None of the patients reported any severe complications or incidences relating to the trial medicine.
Since the trials were a huge success, the company is now planning to apply for an FDA application for Crisaborole. The application is set for the beginning of 2016. Anacor is confident that the FDA approval will not be complex because the trials were a success and will thus provide a compelling argument. The share performance is also a good indicator that the shareholders are also confident about the future of the eczema treatment. The shares went up by roughly 60% on Monday.
The pharmaceutical industry has been very busy especially due to the many acquisitions that have been taking place. Key players such as Sanofi SA (ADR) (NYSE:SNY) have been hard at work trying to perfect their lead drugs. Sanofi and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are currently in phase III trials for an anti-inflammatory drug over which they have partnered up.